Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of BENLYSTA(TM) in Systemic Lupus Erythematosus
November 02, 2009 00:01 ET | Human Genome Sciences
ROCKVILLE, MD and LONDON--(Marketwire - November 2, 2009) - Human Genome Sciences, Inc. (NASDAQ: HGSI) and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab) met the primary...